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In most human diseases where immune com-
plexes have been implicated in the pathologic 
process, the antigen or antigens involved are 
unknown. This fact is particularly true of a number 
of diseases being considered in this symposium. 
Complexes of unknown composition hav.e been 
detected in pathologic fluids from patients with 
dermatitis herpetiformis [1], pemphigus [2], lep-
rosy [3,4], schistosomiasis [5] and, most recently, 
melanoma [6]. One general approach to the detec-
tion of immune complexes where the antigen is 
unknown is to use reagents which will react with 
complexed antibody but not monomeric antibody 
molecules. The ideal reagent should be capable of 
detecting immune complexes of all immunoglobu-
lin classes, both complement fixing and non-com-
plement fixing immune complexes, and immune 
complexes of all sizes but particularly the small 
soluble ones that can persist in the circulation. In 
addition, it should be applicable to a relatively 
simple, sensitive, quantitative assay that lends 
itself to standardization. Needless to say, such a 
reagent does not exist. There are, however, a 
number of methods using biologic reagents which 
react specifically with some types of antibody 
complexes and have been utilized in immune 
complex detection assays. These include both 
molecular and cellular reagents (Table 1). 
The cellular methods utilize various cell recep-
tors or activities specific for complexed globulin. 
They all require living cells and detect complexes 
of IgG only. Two methods have been well charac-
terized. In the Raji cell technique, complexes are 
detected by binding to the C3b or C3d receptors 
that are present on the surface of lymphoblastoid 
cells [7]. The complexes are quantitated by stain-
ing the cells with a fluorescein-labeled anti-IgG 
and counting the number of cells that fluoresce. 
The preparation of cells used in studying human 
immune complexes is intricate since the Fc recep-
tor on the surface of the cells must be blocked with 
IgG and a Fab anti-IgG which will not be detected 
by the fluorescein-labeled antibody. The technique 
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detects only C3-fixing IgG complexes and is most 
sensitive for complexes larger than 198. 
The platelet aggregation reaction is based on the 
phenomenon of interaction of complexes with the 
surface of platelets which causes an alteration 
resulting in platelet aggregation [8 ]. The aggrega-
tion is not based on cross-linking of the platelets by 
complexes but is due to changes in the adhesive 
properties of the platelets. Viable platelets must be 
used in the reaction since the surface alteration in 
the presence of immune complexes is dependent on 
the metabolic state. The technique has proved 
most useful in detecting immune complexes 
involving known viral antigens but can be used as 
well to detect immune complexes where the anti-
gen is unknown [9]. Like the Raji cells, the reaction 
is most sensitive for large complexes; in addition, 
certain nonimmunologic substances can cause ag-
gregation, and rheumatoid factor will inhibit the 
aggregation reaction. 
The third technique is based on IgG complexes 
inhibiting the killing by lymphocytes of anti-
body-sensitized 51Cr-Iabeled target cells [10]. The 
fourth test method is based on inhibition by IgG 
complexes of phagocytosis of 125I-Iabeled IgG com-
plex by pig macrophages [11]. These techniques 
have not as yet been well characterized and will 
not be considered further here. 
In general, the cell methods do not appear as 
promising for the development of a standard assay 
as the molecular methods because of the require-
ment for living cells. The C1q reagent and anti-IgG 
reagents, or rheumatoid factors (RF) as they are 
more often called, more readily lend themselves to 
standardization and utilization in competitive in-
hibition radioimmunoassay and hence appear at 
present to 'be the most promising approach for 
development of standard methods for detecting 
circulating complexes that could be applicable to 
clinical studies. These two methods will be consid-
ered in detail. 
The C1q molecule binds with monomeric IgG1, 
IgG2, IgG3 and IgM [12]. This binding is greatly 
enhanced by aggregation of these immunoglobu-
lins and, under proper conditions, soluble com-
plexes can be precipitated by C1q [13,14]. This 
direct reaction of C1q with aggregated immuno-
globulins can be demonstrated in-gel diffusion (Fig. 
1). Reduction and alkylation of the aggregated 
immunoglobulins, a treatment known to destroy 
the complement-fixing abilities of immunoglobu-
lins, eliminated this reaction with C1q. 
This gel diffusion system has proved useful in 
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TABLE I. Methods employing biologic reagents in the 
detection of immune complexes 
Molecular 
Reaction with C1q 
Reaction with rheumatoid factors 
Cellular 
Binding to Raji cells 
Platelet aggregation 
Inhibition of antibody-mediated lymphocyte cytotoxic-
ity 
Inhibition of macrophage phagocytosis 
FIG. 1. The precipitin reaction between C1q ( well 1) 
and aggregated Ig (well 2) is shown. Reduction and 
alkylation of aggregated Ig (well 3) eliminate the precipi-
tin reaction with C1q but not with purified RF (well 4). 
(Reprinted with permission from [15]) 
studying pathologic fluids [15,16 J. Over the past 
few years a number of characteristics of the system 
have been established which are applicable to the 
new radioimmunoassays being developed. These 
will be reviewed briefly. 
In the gel method, Clq will precipitate only with 
aggregates of immunoglobulins or preformed 
immune complexes that are larger than 198 (Fig. 
2). In addition, substances other than 'Y globulin 
complexes can precipitate with Clq, including 
certain biologic polyanions which can occur in 
some instances in pathologic fluids. The reactions 
with DNA and endotoxin are shown in Figure 3. 
These precipitin reactions with Clq can be differ-
entiated from those given by aggregated Ig by their 
persistence after reduction and alkylation. Also, 
DNAase treatment will destroy the ability of DNA 
to react with Clq. 
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In studying sera of patients with systemic lupus 
erythematosus (8LE); the gel method was found to 
detect Clq precipitins in a high percentage of 
patients with active disease and hypocomplemen-
temia. An example of how this gel method is used 
in screening sera is shown in Figure 4. In some sera 
of patients with 8LE the reactive material 
involved in the precipitation with Clq was shown 
to be of high molecular weight by sucrose density 
gradient ultracentrifugation as would be expected 
for immune complexes. However, in addition to 
high-molecular-weight Clq precipitins, it soon 
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FIG. 2. Sucrose density gradient fractionation of 
aggregated Ig. Precipitation of various sized aggregates 
with C1q or mRF in gel diffusion is indicated at top of 
figure. The positions of the 198 and 6.58 markers are 
indicated. 
FIG. 3. Gel diffusion plate showing the precipitation of 
C1q (well A) with native DNA (well 1) , single-stranded 
DNA (well 2), and endotoxin (well 3). 
FIG. 4. Gel diffusion plate showing the precipitation of 
C1q (well A) with sera from two patients with active 8LE 
and hypocomplementemia (wells 1 and 2). The sera from 
two patients with inactive 8LE are in wells 3 and 4. 
(Reprinted with permission from Agnello V, et al: Kidney 
Intern 3:90, 1973) 
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became apparent that other types consisting of 
low-molecular-weight materials also occurred. 
These were first detected in the course of screening 
a wide variety of patients for C1q precipitins. One 
unusual patient with an erythema multiforme-like 
rash and marked hypocomplementemia was found 
with a strong Clq precipitin of low molecular 
weight [16 J. A sucrose density gradient of the 
reactive material isolated from fresh serum of this 
patient is shown in Figure 5. Subsequently, similar 
patients have been encountered in our laboratory 
and elsewhere [17,18,19,20]. These patients are 
similar to SLE patients in some respects but do not 
meet the diagnostic criteria for SLE. They have in 
common several distinctive clinical and serologic 
findings (Table II). Recurrent rash such as shown 
in Figure 6 was the most prominent feature. 
Arthralgias are a frequent symptom. Angioneurotic 
edema of the face and small bowel occur less 
frequently but severe bouts can occur (Figure 7). 
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FIG. 5. Sucrose density gradient fractionation of the 
isolated Clq reactant from serum of patient PUR. The 
line connecting the open circles shows the distribution of 
the isolated protein in the gradient. The bars show the 
distribution of a 78 'YG marker assayed by hemaglutina-
tion inhibition. Precipitation of the various fractions with 
Clq in gel diffusion is indicated at the top of the figure. 
(Reprinted with permission from [16]) 
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This syndrome, for lack of a better name, has been 
called the SLE related-syndrome. 
Serologically, the striking features were marked 
hypocomplementemia and the presence of low-
molecular-weight Clq precipitins. The exact na-
ture of these low-molecular-weight precipitins is 
not as yet known, but they do not appear to be 
immune complexes. They do appear to be inti-
mately related to the marked hypocomplemen-
temia that occurs in these patients [17 J. 
RF or 19s anti-IgG reagents can be used in a 
similar way to the C1q molecule for detection of 
complexes [5 J. In gel diffusion these reagents can 
precipitate with aggregated IgG (Fig. 1) but not 
monomeric IgG or other immunoglobulins. Mono-
clonal 19s rheumatoid factors (mRF) show a 
greater ability for precipitating complexes than do 
the polyclonal rheumatoid factors (pRF) com-
monly found in sera of patients with rheumatoid 
arthritis [21 J. To a great extent the successful use 
of these reagents in detecting immune complexes 
depends on the mRF selected. There is marked 
variation in the amount of monomeric IgG which 
will inhibit the reaction of different mRF with 
complexed IgG. The greater the affinity of the RF 
for the complexed IgG, the more sensitive the 
method will be when carried out in the presence of 
large amounts of. monomeric IgG. Also, these 
reagents will precipitate with small aggregates of 
IgG that escape precipitation with most pRF or 
Clq as demonstrated in Figure 2. C1q , as shown 
earlier, will detect only complexes larger than 19s 
whereas mRF will detect complexes as small as 
approximately 8S. 
This greater sensitivity of mRF for small com-
plexes is demonstrated in comparing the reactions 
of C1q and mRF with sera and synovial fluids from 
patients with rheumatoid arthritis. Figure 8 shows 
such a study on the serum and synovial fluid from 
one patient. C1q reacts with the joint fluid which 
contains complexes larger than 19s but not with 
the serum which contains only complexes smaller 
than 19s. mRF reacts with both serum and joint 
fluid. These results are consistent with the in vivo 
TABLE II. Clinical data on 4 patients with marked hypocomplementemia, cutaneous rash, and serum 
C1q precipitins 
PUR BLO eIe SPI 
Sex Female Female Female Female 
Age 32 years 32 years 39 years 32 years 
Duration of symptoms 5 years 2 years 2 years 2 years 
Rash ++++ +++ ++ +++ 
Arthralgia ++++ ++ + ++ 
"' Angioneurotic" edema + ++ +++++ + 
ANF 0 . ->1+ 1+ 1+ 0 
LE cells 0 0 0 0 
Serum 'Y globulin Elevated Normal Elevated Elevated 
CH50a <30 <30 < 30 56 
Serum Clq precipitins +++ ++ + ++ 
a Normal range 150-250 
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FIG. 6. Picture of patient PUR. Similar rashes oc-
curred in all patients in Table II in association with Clq 
precipitins and marked complement depression in the 
serum. 
complement findings which show a normal hemo-
lytic complement level in the serum but depressed 
levels in the joint fluid. 
The gel methods are simple and useful in study-
ing pathologic fluids in which high concentrations 
of complexes are present, such as in sera of patients 
with SLE and in synovial fluids from patients with 
rheumatoid arthritis, but lack the sensitivity and 
quantitative capacity needed for wide application. 
Radioimmunoassay methods using Clq or mRF 
have considerably greater quantitative capacity 
than the gel methods and improved sensitivity. 
In Table III the sensitivities of radioimmunoas-
says employing Clq and rheumatoid factors are 
compared to that of a gel diffusion technique. The 
minimum concentration of heat-aggregated IgG 
which can be detected by the different methods is 
shown. Aggregated IgG was chosen because of the 
comparative data available. The Clq gel method 
under optimum conditions can detect complexes at 
a concentration of 100 JLg/ml. The C1q-poly-
ethylene glycol (PEG) method [22] utilized 1251_ 
labeled C1q and is based on two principles: the 
binding of C1q to complexes and the precipitation 
of immune complexes at a critical concentration of 
PEG. The C1q measured in the PEG precipitate 
can be taken as a measure of complexes in the 
serum. The method increases the sensitivity for 
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detection of IgG complexes 2-fold over the gel 
method. However, it is more sensitive for other 
types of complexes. 
The C lq deviation test [23] offers greater sensi-
tivity. In this method, complexes are quantitated 
by determining the inhibition of 125I_Clq binding 
to red blood cells sensitized with IgG antibody. A 
20-fold greater sensitivity over the gel method has 
thus far been obtained. 
The gel method employing mRF has about the 
same sensitivity as the Clq gel method. Only one 
radioimmunoassay has thus far been reported that 
utilizes mRF [24]. This also is a competitive 
inhibition system, with complexes being quanti-
tated by determining the inhibition of 125I-Iabeled 
IgG binding to a solid phase mRF. A 4-fold in-
crease in sensitivity over the gel method has been 
observed. 
By far the most sensitive radioimmunoassay of 
those compared in Table II is that employing a 
pRF in a piggy-back system [25]. Complexes are 
quantitated by determining inhibition of the reac-
tion of pRF with 125I-Iabeled aggregated IgG. The 
pRF is precipitated with an anti-IgM and the 
counts precipitated taken as a measure of the 
aggregated 125I_IgG binding by pRF. This method 
detects immune complexes in the range of 350 ng. 
This sensitivity is not strictly comparable with the 
others since this is for a specific antigen-antibody 
complex. In addition, the system is inhibited in the 
presence of high concentrations of monomeric IgG, 
and RF also interfere. 
Two new competitive inhibition radioim-
munoassays are currently being developed in our 
laboratory and are designed to overcome some of 
the differences in the tests currently available. The 
need for heating test serum specimens, which is 
required in both the Clq-PEG test and the Clq 
deviation test, has been eliminated and the speci-
ficity for complexed IgG is sufficiently great to 
eliminate interference of monomeric IgG. 1251_ 
labeled mRF is used in one test, 125I_C1q in the 
other. In both, IgG-Sepharose is used as the 
binding substrate and a two-step inhibition-bind-
ing method is used that requires a total of 5 hr to 
perform. Figure 9 shows some preliminary data 
using the mRF binding inhibition assay. Thus far 
the lower limit of sensitivity for detection of 
aggregated IgG is 0.5 JLg/ml (0.05 f.Lg, absolute 
amount). Monomeric IgG does inhibit but there is 
approximately a two-log greater sensitivity for 
com plexes of IgG. 
Some results, also preliminary, using the 
125I_C1q binding inhibition assay are shown in Fig-
ure 10. The lower limit of sensitivity for detection 
of aggregated IgG is currently 3.8 JLg/ml (0.38 f.Lg, 
absolute amount). Monomeric IgG does not give 
any significant inhibition in this system. However, 
certain polyanionic substances can give greater 
inhibition than complexed IgG as shown by the 
SDNA example in Figure 10. 
It is apparent that one must be aware of the 
non-immune substances which can react with C1q; 
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FIG. 7. Upper gastrointestinal x-ray examinations on patient CIC. a: During attack of angioneurotic edema. Film 
shows edema of wall (large arrow) and narrowing of lumen of small bowel (small arrow). b: Similar study 1 week after 
the attack. Attack was associated with C1 precipitins and marked complement depression in the serum. 
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FIG. 8. Comparison of monoclonal anti-IgG (RF) and 
C1 q precipitation reactions with serum (RAS) and joint 
fluid (RAJF) from a patient with rheumatoid arthritis. 
Normal serum (NS) and aggregate IgG (Agg -yG) are 
present as controls. 
however, some of these substances in pathologic 
fluids appear to be of considerable interest rather 
than merely a hindrance to quantitation of 
immune complexes. 
In one instance a low-molecule-weight C1q re-
actant may be a marker for a distinct syn-
drome-the SLE-related syndrome [17]. Recently 
a C1q reactant which does not appear to be an 
immune complex has been shown to correlate with 
disease activity in the Denque shock syndrome [7]. 
Thus, even though the identities of these sub-
stances are not known, their qu\antitation may be 
of use clinically. 
To review the application of the Clq and RF 
methods: The C1q method is useful in detecting 
and quantitating complement-fixing immune com-
plexes of the IgG and IgM type, but certain 
non-immune substances are also detected. The use 
TABLE III. Minimal concentration of soluble 
heat-aggregated Ig detectable by various immune 
complex tests 
Test 
Clq gel diffusion 
Clq-PEG radioimmunoassay 
Clq deviation 
mRF gel diffusion 
mRF quantitative precipitins 
mRF radioimmunoassay 
pRF radioimmunoassay 
Aggregated Ig 
(JIg/ ml) 
100 
50 
5 
100 
1 
25 
0.35 0 
o Soluble tetanus toxoid-antitoxoid complexes; no 
data available for heat-aggregated Ig. 
of mRF is limited to the detection of immune 
complexes of the IgG type but can detect smaller 
complexes than the C1q method as well as non-
complement-fixing immune complexes. In addi-
tion, the mRF reagents have greater specificity for 
IgG complexes since they do not react with non-
immune substances. 
Neither the C1q nor the RF methods differenti-
ate reactions due to immune complexes from those 
due to nonspecific ally aggregated immuno-
globulins. 
In conclusion, it appears that radioimmunoas-
says employing the C lq and mRF reagents at 
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FIG. 9. Inhibition of binding of 125I_mRF to IgG-
Sepharose by increasing amounts of aggregated IgG (agg 
IgG) and monomeric IgG. 
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FIG. 10. Inhibition of binding of 125I_C1q to IgG-
Sepharose by increasing amounts of aggregated IgG (agg 
IgG), monomeric IgG, and single-stranded DNA 
(ssDNA) . 
present appear to be the best approach to the 
development of standard assays for detection of 
immune complexes. 
The potential enhanced sensitivity offered by 
radioimmunoassay has not been realized thus far 
and additional technical refinement is needed 
before these assays will be of practical clinical use. 
However, the work done so far with the Clq and RF 
reagents appears to provide a solid base for further 
development. 
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DISCUSSION 
Turk: I am concerned not about increasing the 'speci-
ficity of C1q binding, but about the lack of specificity of 
this reaction . I feel that increasing the sensitivity of this 
and similar reactions is not the answer to the problem of 
diagnosis in immune complex disease. One should be 
devising techniques for detecting complexes depending 
on their content of specific antigen. Dr. Reichlin, when he 
spent a year with us, helped to develop such a technique 
for the detection of immune complexes containing myco-
bacterial antigens. This technique depended on the 
precipitation of immunoglobulin with an anti-immuno-
globulin serum. Then the presence of mycobacterial 
antigen can be detected by the use of a radiolabeled 
antimycobacterial antiserum. This technique has been 
used so far by Drs. Reichlin and Taverne to detect 
specific immune complexes in the serum of mice infected 
with Mycobacterium leprae nurium [Taverne , et al Clin. 
Exp Immunol (in press)]. In addition, one should also 
consider that the presence of immune complexes in the 
serum might not be the answer. Immune complex deposi-
tion in vasculitis might occur from the direct interaction 
of antigen and antibody in the vessel wall and not from 
the deposition of preformed complexes present in the 
circulation. 
Agnello: We don't know at present what the relative 
importance of immune complexes is in the pathogenesis 
of cutaneous disorders; however, there is suggestive evi-
dence that such a mechanism may be of importance and 
those clues must be pursued. Reagents with greater 
specificity for immune complexes would be desirable to 
have, but the reagents that we have at present, when 
used correctly, can provide useful data. I think the 
approach of looking for specific antigens that you referred 
to would be unproductive considering the virtually limit-
less number of possible antigens which could be involved. 
A more productive approach might be to isolate any 
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immune complexes of unknown composition with Clq or 
monoclonal RF and then attempt to characterize any 
antigen precipitated. 
Gigli: Kinetic studies of the clearance of immune 
complexes in the Arthus reaction indicate that they are 
removed very early in the reaction. Therefore, in fully 
developed lesions of immune. complex vasculitis, one 
would not expect to detect them. 
. Turk: I agree that immunoglobulin and complement 
deposition may only be demonstrated in the Arthus 
reaction in guinea pigs during the first 2 hr after antigen 
injection. After the reaction has developed fully they may 
be difficult to demonstrate. Allergic vasculitis lesions, 
however, occur in crops and it should not be too difficult 
to demonstrate complexes in early lesions, as one can in 
erythema nodosum leprosum. 
Claman: I would like to take a position between Dr. 
Agnello and Dr. Turk. In our studies of generalized 
vasculitis not associated with connective tissue disease 
(over 40 cases), we worked on the hypothesis that this is 
an immune complex disease. However, in only 1 case was 
there consistent evidence of circulating complexes (low 
CH50, low complement components) and this case had 
disseminated histoplasmosis . All the others had no evi-
dence of circulating immune complexes (except for 
cryoproteins). Either vasculitis is not an immune com-
plex disease, or the current tests are not good enough, or 
the complexes are only intermittently present in the 
circulation. We have been looking for footprints of 
complexes in the tissues and Dr. Sams has shown by 
immunofluorescence the presence of C3 or IgM or IgG in 
both the lesions of vasculitis and in normal skin. 
Perhaps this is a better place to look than in the 
circulation. 
Braverman: You can find electron-dense deposits in 
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normal-appearing skin before lesions occur as well as in 
the early stages of the spontaneous vasculitic lesion by 
electron microscopy and immunofluorescent techniques. 
The problem is the identification of the nature of the 
antigen. 
Gigli: What is the evidence to supoort the concept that 
the dense bodies seen in electron microscopy represent 
immune complexes? 
Braverman: Electron-dense deposits in our vasculitic 
lesions are identical in appearance to those found in 
lupus nephritis and streptococcal glomerulonephritis, 
where they have been shown to contain immunoglobulins 
by ferritin-labeled antibodies. In addition we have found 
crystalloid-like deposits (fingerprint pattern) both in the 
vasculitic lesions and kidneys of one patient with SLE. 
This type of deposit has been reported previously by 
Churg in lupus skin and renal lesions. The crystalline 
appearance can be shown to merge into the usual 
amorphous character of the deposits. The fingerprint also 
acts as a marker for the deposit. The amorphous electron-
dense deposit has a characteristic appearance so that it 
is easily identified and not confused with other types of 
electron-dense material. 
Tan: I would like to make a comment in regard to what 
Dr. Turk said. He is perfectly right in saying that it is 
important to identify the specific types of immune 
complexes with which one is dealing. How~ver, I am sure 
he would also agree that as a first step in that direction, it 
would be important to be able to say that one is dealing 
with a disease or a particular situation where soluble 
immune complexes might play important roles in patho-
genesis. It is for that reason that the tests described by 
Dr. Agnello, although not allowing us to characterize the 
specificity of the immune system, still tell us that we are 
dealing with immune complexes . 
